Cantor Fitzgerald lowered the firm’s price target on Rapt Therapeutics to $40 from $44 and keeps an Overweight rating on the shares following the Q4 results. The readout timeline for the Phase 2B trial of RPT193 in atopic dermatitis is delayed to mid-2024 from the firm’s prior expectation of 4Q23 due to slower-than-expected patient enrollment driven by seasonality, the analyst tells investors in a research note. Rapt is looking at steps to speed up enrollment, the firm says, adding that the delay is not driven by any concerns related the drug and would be a buyer here.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT:
- Rapt Therapeutics Craters as Testing Proves a Challenge
- RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
- Rapt Therapeutics reports Q4 EPS (64c), consensus (66c)
- Rapt Therapeutics says $2M of cash held at Silicon Valley Bank
- RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue